| VOL. 28, NO. 2 | May, 2003 |
|---|
| John R. Glowa, Ph.D. Pfizer Global Res & Devel CNS Discovery Groton Laboratories Eastern Point Rd MS8220-4188 Groton, CT 06340 tel: (860) 686-1835 email: john_glowa@groton.pfizer.com |
Michael A. Nader, Ph.D. Department of Physiology & Pharmacology Wake Forest University School of Medicine Medical Center Blvd. Winston-Salem, NC, 27157 tel: (336) 713-7172 email: mnader@wfubmc.edu |
| Jonathan B. Kamien, Ph.D. BioPsych Consulting 3450 Vista Haven Road Sherman Oaks, CA 91403 email: jkamien@biopsych.com |
Marilyn E. Carroll, Ph.D. Dept. of Psychiatry University of Minnesot Box 392 UMHC Minneapolis, MN 554544 (612) 626-6289 email: mcarroll@staff.tc.umn.edu |
ISGIDAR e-mail address: ISGIDAR-L@venus.vcu.edu
INDEX
The 2003 annual ISGIDAR Scientific Meeting will be held at the Sheraton Bal Harbour Beach Resort in Miami Beach, Florida immediately preceding the annual scientific meeting of the College on Problems of Drug Dependence. ISGIDAR registration will begin at 8:00AM on Saturday, June 14, 2003. The registration fee is $50. Paper presentations will be scheduled between 9:00AM and 5:00PM and the business meeting will be held from 5:00 to 5:30 PM.
If you wish to advance register ($50 does not include lunch), please send a check, payable to ISGIDAR, to Dr. Marilyn Carroll, Psychiatry Department, Box 392 UMHC, University of Minnesota, Minneapolis, MN 55455. Receipts for meal costs and registration will be provided at the meeting.
President Glowa has arranged lunch at a cost of $28 per person. We have the capacity to seat 48 people at lunch and that number is fast approaching. If you intend to eat lunch at the meeting, please respond to Jace Glowa ASAP (john_glowa@groton.pfizer.com).
Nominations for new members should be e-mailed to the President of ISGIDAR and will be collated for a vote by ballot preceding the next annual meeting.
According to the By-Laws, the terms of the President and Secretary are two years. The Secretary has traditionally taken the Office of President at such junctures, and we will need to nominate a new Secretary this year. Nominations for Secretary can be e-mailed to the President of ISGIDAR or made on the floor of the business meeting, and will be voted on during that meeting. We also perpetually seek someone to relieve our Treasurers annual burden, while we thank her for her patience and performance.
8:00 Registration, coffee
8:30 Opening comments:Jace Glowa, President
8:40 Opioids, cocaine, and food change runtime distribution in a rat runway procedure.Gerald Zernig, University of Innsbruck, Austria
9:00 Using growth-curve modeling to describe and analyze the acquisition of drug self-administration in laboratory animals. Eric Donny, Johns Hopkins University.
9:20 Student Travel Award Winner- Subjective and reinforcing effects of smoking during negative affect. Cynthia Conklin, University of Pittsburgh.
9:40 The reinforcing, subject-rated, and physiological effects of intranasal methylphenidate in humans. A dose-response analysis. William Stoops, University of Kentucky.
10:00 Coffee Break
10:30 Symposium: Agonist pharmacotherapy: Pro and Con, Introduction by Michael Nader
12:00 Lunch
1:30 Cocaine addiction: lessons learned. Kathleen M. Kantak, Boston University.
1:50 Recent findings on the reinforcing effects of cannabinoids. Steve Goldberg, NIDA Intramural Research
2:10 New evidence for opioid-cannabinoid interactions in drug-discrimination and drug self-administration models. Marcello Solinas, NIDA Intramural Research
2:30 The behavioral significance of nicotine's differential ability to desensitize brain area nAChR's as evaluated in both a drug discrimination and cellular receptor model. Randy Jones, Virginia Commonwealth University.
2:50 Coffee Break
3:10 Price-based remifentanil choice in rhesus monkeys. Gail Winger, University of Michigan
3:30 Effects of response-contingent and non-contingent intravenous fentanyl on quantitative EEG activity in opiod-dependent volunteers. Mark Greenwald, Wayne State University
3:50 Intravenous self-administration of the endocannabinoid anandamide by squirrel monkeys and effects of CB1-receptor blockade and inhibition of anandamide transport. Zuzana Justinova, NIDA Intramural Research
4:15 Business Meeting
4:30 Refreshments